Showing 161 - 180 results of 44,700 for search '(( significant case based ) OR ( significant changes decrease ))', query time: 0.61s Refine Results
  1. 161
  2. 162
  3. 163
  4. 164
  5. 165
  6. 166
  7. 167

    The base case analysis. by Wenwang Lang (20293527)

    Published 2025
    “…</p><p>Results</p><p>In the base-case scenario, adding benmelstobart and anlotinib to chemotherapy increased QALYs by 0.34 at an additional cost of $24,684.07, yielding an ICER of $71,559.84 per QALY. …”
  8. 168
  9. 169

    Base-case results. by Shuo Kang (1306860)

    Published 2025
    “…One-way and probabilistic sensitivity analyses were conducted to estimate the robustness of the model results,</p><p>Results</p><p>In base-case analysis, compared with toripalimab plus chemotherapy and chemotherapy alone, ITH-testing directed therapy could bring additional 0.14 QALYs and 0.29 QALYs, with marginal costs of $3750.75 and $7778.18, resulting in the ICER of $27,353.27/QALY and $26,461.46/QALY, respectively, which lower than the Chinese willingness-to-pay (WTP) threshold. …”
  10. 170
  11. 171
  12. 172

    Base-case results. by Mingxi Xie (19812594)

    Published 2024
    “…The model time-frame was one-year. Base-case analysis and sensitivity analysis were performed. …”
  13. 173

    Base-case analysis. by Akiko Kowada (14659965)

    Published 2023
    “…The willingness-to-pay (WTP) threshold was set at US$50,000 per QALY gained. In the base-case analysis, HTLV-1 antenatal screening (US$76.85, 24.94766 QALYs, 24.94813 LYs, ICER; US$40,100 per QALY gained) was cost-effective compared with no screening (US$2.18, 24.94580 QALYs, 24.94807 LYs). …”
  14. 174
  15. 175

    Fig 5 - by Xiaoqing Chen (89898)

    Published 2023
    Subjects:
  16. 176
  17. 177
  18. 178
  19. 179
  20. 180